Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Leases: 2022-2025

Historic Current Leases for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $1.9 million.

  • Immunocore Holdings' Current Leases rose 71.19% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 71.19%. This contributed to the annual value of $1.5 million for FY2024, which is 11.46% up from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Current Leases is $1.9 million, which was up 1.90% from $1.8 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Current Leases high stood at $1.9 million for Q4 2022, and its period low was $1.1 million during Q3 2024.
  • Over the past 3 years, Immunocore Holdings' median Current Leases value was $1.5 million (recorded in 2023), while the average stood at $1.5 million.
  • Its Current Leases has fluctuated over the past 5 years, first dropped by 26.25% in 2023, then skyrocketed by 71.19% in 2025.
  • Quarterly analysis of 4 years shows Immunocore Holdings' Current Leases stood at $1.9 million in 2022, then declined by 26.25% to $1.4 million in 2023, then rose by 11.46% to $1.5 million in 2024, then soared by 71.19% to $1.9 million in 2025.
  • Its Current Leases was $1.9 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.7 million in Q1 2025.